#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Pneumagen, a clinical-stage biotech company, reporting successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil, demonstrated from a Phase 2a influenza human challenge study conducted by hVIVO. The randomised, double-blind, placebo-controlled study enrolled 104 healthy adult volunteers, recruited through the FluCamp platform, and evaluated two dose regimens…

#ORPH Open Orphan PLC – Positive results from RSV Human Challenge Study February 17, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated February 17 2022 from Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, on positive results from a human challenge study assessing its respiratory syncytial virus (“RSV”) antiviral candidate, EDP-938. The results…

#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

#ORPH Open Orphan PLC – Positive results from RSV Human Challenge Study February 17, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL